Fmr LLC Purchases 12,397 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Fmr LLC raised its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 22.9% in the third quarter, HoldingsChannel reports. The firm owned 66,423 shares of the specialty pharmaceutical company’s stock after buying an additional 12,397 shares during the quarter. Fmr LLC’s holdings in KalVista Pharmaceuticals were worth $769,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in KALV. Bank of New York Mellon Corp increased its stake in shares of KalVista Pharmaceuticals by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 135,600 shares of the specialty pharmaceutical company’s stock worth $1,597,000 after purchasing an additional 23,547 shares in the last quarter. nVerses Capital LLC bought a new position in shares of KalVista Pharmaceuticals in the second quarter worth about $25,000. Rhumbline Advisers raised its stake in shares of KalVista Pharmaceuticals by 12.5% in the second quarter. Rhumbline Advisers now owns 53,228 shares of the specialty pharmaceutical company’s stock worth $627,000 after buying an additional 5,908 shares during the period. ClariVest Asset Management LLC lifted its position in shares of KalVista Pharmaceuticals by 2.8% during the 2nd quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company’s stock valued at $673,000 after buying an additional 1,535 shares in the last quarter. Finally, Nicholas Investment Partners LP grew its stake in shares of KalVista Pharmaceuticals by 0.9% during the 2nd quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company’s stock valued at $2,172,000 after acquiring an additional 1,714 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms have commented on KALV. Needham & Company LLC restated a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 7,627 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $9.75, for a total transaction of $74,363.25. Following the completion of the transaction, the chief executive officer now owns 274,596 shares in the company, valued at $2,677,311. This trade represents a 2.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Paul K. Audhya sold 8,077 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $74,793.02. Following the completion of the sale, the insider now directly owns 94,199 shares in the company, valued at $872,282.74. This trade represents a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,291 shares of company stock valued at $304,086 in the last three months. 10.50% of the stock is currently owned by corporate insiders.

KalVista Pharmaceuticals Trading Down 3.4 %

Shares of KALV opened at $8.65 on Wednesday. The business’s 50 day moving average is $10.60 and its 200 day moving average is $11.73. KalVista Pharmaceuticals, Inc. has a 12-month low of $8.48 and a 12-month high of $16.88. The company has a market capitalization of $427.47 million, a PE ratio of -2.38 and a beta of 0.85.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).